GlaxoSmithKline, the pharmaceutical company, may enter a swap to hedge the interest-rate risk on a GBP1 billion (USD1.46 billion) fixed-rate bond it recently offered. In the swap the company would look to receive the coupon on the bond, 5.25%, and pay a LIBOR-based floating rate. Sarah-Jane Chilver-Stainer, group treasurer in London, said GSK sold the 30-year bonds with a fixed coupon because it was attracted by the rate. Credit Suisse First Boston and Schroder Salomon Smith Barney led the deal. It will keep the proceeds in sterling, which Chilver-Stainer called the company's natural currency. She declined comment on the rate it would look to pay and the maturity.
December 24, 2001